SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-005180
Filing Date
2021-01-08
Accepted
2021-01-08 16:02:00
Documents
19
Period of Report
2021-01-04
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d95890d8k.htm   iXBRL 8-K 31704
2 EX-1.1 d95890dex11.htm EX-1.1 265931
3 EX-4.1 d95890dex41.htm EX-4.1 63124
4 EX-5.1 d95890dex51.htm EX-5.1 8878
5 EX-99.1 d95890dex991.htm EX-99.1 9861
6 EX-99.2 d95890dex992.htm EX-99.2 11312
10 GRAPHIC g95890dsp44.jpg GRAPHIC 3879
11 GRAPHIC g95890g0107151544724.jpg GRAPHIC 2744
  Complete submission text file 0001193125-21-005180.txt   626354

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA fate-20210104.xsd EX-101.SCH 3092
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE fate-20210104_lab.xml EX-101.LAB 18137
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fate-20210104_pre.xml EX-101.PRE 11422
12 EXTRACTED XBRL INSTANCE DOCUMENT d95890d8k_htm.xml XML 3402
Mailing Address 3535 GENERAL ATOMICS COURT SUITE 200 SAN DIEGO CA 92121
Business Address 3535 GENERAL ATOMICS COURT SUITE 200 SAN DIEGO CA 92121 858.875.1803
FATE THERAPEUTICS INC (Filer) CIK: 0001434316 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36076 | Film No.: 21517474
SIC: 2836 Biological Products, (No Diagnostic Substances)